HRMY - CIK 0001802665
The table below shows Harmony Biosciences Holdings, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $348.20M | $219.82M | $219.39M | $144.47M | $98.56M | -$2.98M |
| Capital expenditure | $310.00K | $1.15M | $312.00K | $172.00K | $298.00K | $2.00K |
| Investing cash flow | -$39.65M | -$67.48M | -$46.44M | -$141.83M | -$100.30M | -$2.00M |
| Dividends paid | - | - | - | - | - |
Harmony Biosciences Holdings, Inc. reported operating cash flow of $348.20M for fiscal year 2025. That is up 58.4% from $219.82M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow grew from -$75.44M (FY 2019) to $348.20M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | $100.00M | - | - | $167.00K |
| Financing cash flow | -$9.05M | -$11.00M | -$105.55M | $6.84M | $7.42M | $209.16M |